Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers

被引：53

作者：

Pillow, Thomas H. ^{[1
]}

Schutten, Melissa ^{[1
]}

Yu, Shang-Fan ^{[1
]}

Ohri, Rachana ^{[1
]}

Sadowsky, Jack ^{[1
]}

Poon, Kirsten Achilles ^{[1
,4
]}

Solis, Willy ^{[1
,5
]}

Zhong, Fiona ^{[1
]}

Del Rosario, Geoffrey ^{[1
]}

Go, Mary Ann T. ^{[1
]}

Lau, Jeffrey ^{[1
]}

Yee, Sharon ^{[1
]}

He, Jintang ^{[1
]}

Liu, Luna ^{[1
]}

Ng, Carl ^{[1
]}

Xu, Keyang ^{[1
]}

Leipold, Douglas D. ^{[1
]}

Kamath, Amrita V. ^{[1
]}

Zhang, Donglu ^{[1
]}

Masterson, Luke ^{[2
]}

Gregson, Stephen J. ^{[2
]}

Howard, Philip W. ^{[2
]}

Fang, Fan ^{[3
]}

Chen, Jinhua ^{[3
]}

Gunzner-Toste, Janet ^{[1
]}

Kozak, Katherine K. ^{[1
]}

Spencer, Susan ^{[1
]}

Polakis, Paul ^{[1
]}

Polson, Andrew G. ^{[1
]}

Flygare, John A. ^{[1
]}

Junutula, Jagath R. ^{[1
,6
]}

机构：

[1] Genentech Inc, San Francisco, CA 94030 USA

[2] Spirogen Ltd, QMBInnovat Ctr, London, England

[3] WuXi AppTec Co Ltd, Shanghai, Peoples R China

[4] Denali Therapeut, San Francisco, CA USA

[5] Bristol Myers Squibb, Princeton, NJ USA

[6] Cellerant Therapeut, San Carlos, CA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2017年 / 16卷 / 05期

关键词：

BIOLOGICAL EVALUATION; TARGETED TREATMENT; CANCER-THERAPY; IN-VIVO; DESIGN; CHEMISTRY; SELECTION; STABILITY; LYMPHOMA; DELIVERY;

D O I：

10.1158/1535-7163.MCT-16-0641

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. (C) 2017 AACR.

引用

页码：871 / 878

页数：8

共 50 条

[31] Self-Assembled L-DNA Linkers for Rapid Construction of Multi-Specific Antibody-Drug Conjugates Library
Zhou, Liujuan
Yang, Fan
Bai, Zhaoshuai
Zhou, Xiaohui
Zhang, Zhihai
Li, Zhihang
Gong, Junyuan
Yu, Junqi
Pan, Liqiang
Cao, Chan
Chou, James J.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2023, 62 (27)
[32] Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
Hinrichs, Mary Jane Masson
Ryan, Pauline M.
Zheng, Bo
Afif-Rider, Shameen
Yu, Xiang Qing
Gunsior, Michele
Zhong, Haihong
Harper, Jay
Bezabeh, Binyam
Vashisht, Kapil
Rebelatto, Marlon
Reed, Molly
Ryan, Patricia C.
Breen, Shannon
Patel, Neki
Chen, Cui
Masterson, Luke
Tiberghien, Arnaud
Howard, Phillip W.
Dimasi, Nazzareno
Dixit, Rakesh
CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5858 - 5868
[33] Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates
Liu-Shin, Lily
Fung, Adam
Malhotra, Arun
Ratnaswamy, Gayathri
MABS, 2018, 10 (04) : 583 - 595
[34] Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice
Anami, Yasuaki
Yamazaki, Chisato M.
Xiong, Wei
Gui, Xun
Zhang, Ningyan
An, Zhiqiang
Tsuchikama, Kyoji
NATURE COMMUNICATIONS, 2018, 9
[35] A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
Miller, Michael L.
Fishkin, Nathan E.
Li, Wei
Whiteman, Kathleen R.
Kovtun, Yelena
Reid, Emily E.
Archer, Katie E.
Maloney, Erin K.
Audette, Charlene A.
Mayo, Michele F.
Wilhelm, Alan
Modafferi, Holly A.
Singh, Rajeeva
Pinkas, Jan
Goldmacher, Victor
Lambert, John M.
Chari, Ravi V. J.
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1870 - 1878
[36] Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity
Nervig, Christine S.
Rice, Megan
Marelli, Marcello
Christie, R. James
Owen, Shawn C.
BIOCONJUGATE CHEMISTRY, 2025, 36 (02) : 190 - 202
[37] Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity
Aoyama, Michihiko
Tada, Minoru
Yokoo, Hidetomo
Ito, Takahito
Misawa, Takashi
Demizu, Yosuke
Ishii-Watabe, Akiko
BIOCONJUGATE CHEMISTRY, 2024, 35 (10) : 1568 - 1576
[38] Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis
Suzuki, Yukio
Zhou, Susu
Ota, Yukihide
Harrington, Matthew
Miyagi, Etsuko
Takagi, Hisato
Kuno, Toshiki
Wright, Jason D.
JNCI CANCER SPECTRUM, 2023, 7 (05)
[39] Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
Lyon, Robert P.
Setter, Jocelyn R.
Bovee, Tim D.
Doronina, Svetlana O.
Hunter, Joshua H.
Anderson, Martha E.
Balasubramanian, Cindy L.
Duniho, Steven M.
Leiske, Chris I.
Li, Fu
Senter, Peter D.
NATURE BIOTECHNOLOGY, 2014, 32 (10) : 1059 - +
[40] Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index
Wang, Yanming
Xie, Fei
Liu, Lianqi
Xu, Xin
Fan, Shiyong
Zhong, Wu
Zhou, Xinbo
DRUG DELIVERY, 2022, 29 (01) : 754 - 766

← 1 2 3 4 5 →